Want to see CYAN full AI Analyst Report?
CYAN Stock Chart & Stats
$0.45
$0.00(0.00%)
At close: 4:00 PM EDT
$0.45
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.23 - $0.57
Previous CloseN/A
Volume60.00
Average Volume (3M)3.84K
Market Cap
$2.78M
Enterprise Value$12.96
Total Cash (Recent Filing)$1.09M
Total Debt (Recent Filing)$11.37M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding7,392,243
10 Day Avg. Volume1,653
30 Day Avg. Volume3,840
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.28
Price to Sales (P/S)0.10
P/FCF Ratio-1.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue StabilizationRevenue growth of about 5% in each of 2025 and 2026 indicates stabilization after prior weakness and provides a base for rebuilding scale. If maintained, improving demand can support better utilization of the algae platform and help spread fixed costs across a larger sales base.
Margin RecoveryThe gross-margin rebound and return to positive EBITDA show meaningful operational improvement, even though profitability is incomplete. Sustaining these gains could strengthen the economics of algae cultivation and processing while moving the company closer to covering its fixed-cost structure.
Algae Product PlatformCyanotech operates across established algae-based ingredient and supplement applications rather than relying on a single product use. Spirulina and astaxanthin serve consumer and business markets, creating a platform for recurring product development and broader commercial reach.
Bears Say
Persistent LossesDespite improvement from the 2024 trough, continued net losses and negative operating income show that the turnaround has not yet become self-sustaining. The company remains exposed to execution risk because its current revenue base does not fully cover operating costs.
Rising LeverageRising leverage alongside a shrinking equity base reduces financial flexibility and increases the burden on future operating improvements. Higher debt relative to shareholder capital can constrain investment and make the business less resilient if profitability recovery takes longer than expected.
Fragile Cash GenerationCash generation only turned slightly positive in 2026 and remains small relative to the company’s earnings profile. The sharp decline in free cash flow versus 2025 suggests limited internally funded capacity, leaving less room to absorb weaker conditions or support needed investment.
Cyanotech News
CYAN FAQ
What was Cyanotech’s price range in the past 12 months?
Cyanotech lowest stock price was $0.23 and its highest was $0.57 in the past 12 months.
What is Cyanotech’s market cap?
Cyanotech’s market cap is $2.78M.
When is Cyanotech’s upcoming earnings report date?
Cyanotech’s upcoming earnings report date is Nov 18, 2026 which is in 46 days.
How were Cyanotech’s earnings last quarter?
Cyanotech released its earnings results on Jun 30, 2026. The company reported -$0.018 earnings per share for the quarter.
Is Cyanotech overvalued?
According to Wall Street analysts Cyanotech’s price is currently Overvalued.
Does Cyanotech pay dividends?
Cyanotech does not currently pay dividends.
What is Cyanotech’s EPS estimate?
Cyanotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyanotech have?
Cyanotech has 7,392,243 shares outstanding.
What happened to Cyanotech’s price movement after its last earnings report?
Cyanotech reported an EPS of -$0.018 in its last earnings report. Following the earnings report the stock price went up 9.783%.
Which hedge fund is a major shareholder of Cyanotech?
Currently, no hedge funds are holding shares in CYAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cyanotech
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids. Beyond its product lines, Cyanotech also offers contract extraction services. The company reaches its customers through a diverse array of sales channels, encompassing third-party distributors, retailers, and online platforms, as well as direct sales to consumers. Additionally, it supplies products in bulk to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries.
Technical Analysis
Nature's Sunshine Products
―
Seneca Foods
―
Hain Celestial
―
USANA Health
―
Laird Superfood
―
Ownership Overview
30.67% Insiders
―
Mutual Funds
― Other Institutional Investors
69.33% Public Companies and
Individual Investors